Literature DB >> 11481525

Cutaneous signet ring cell carcinoma: a report of a case and review of the literature.

C González-Lois1, J L Rodríguez-Peralto, R Serrano-Pardo, M A Martínez-González, F López-Ríos.   

Abstract

Primary cutaneous signet-ring cell carcinoma (CSRCC) is a very unusual but distinctive clinicopathologic entity. It is defined as a diffuse malignant epithelial neoplasia localized in dermis and subcutis without epidermal involvement, showing variable amounts of signet ring cells, without evidence of a visceral adenocarcinoma. We report a case of CSRCC in a 70-year-old man along with its histologic and ultrastructural characteristics, and review of previous cases. We describe their main diagnostic features and discuss its wide differential diagnosis.

Entities:  

Mesh:

Year:  2001        PMID: 11481525     DOI: 10.1097/00000372-200108000-00009

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  4 in total

1.  A Case of Metastatic Gastric Adenocarcinoma Mimicking Preseptal Cellulitis.

Authors:  Kwang Hee Won; Mi Hye Lee; Woo Jin Lee; Chong Hyun Won; Sung Eun Chang; Jee Ho Choi; Kee Chan Moon; Mi Woo Lee
Journal:  Ann Dermatol       Date:  2015-07-29       Impact factor: 1.444

2.  A brief review of different types of sweat-gland carcinomas in the eyelid and orbit.

Authors:  Leilei Zhang; Shengfang Ge; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2013-04-09       Impact factor: 4.147

3.  Diagnostic and treatment challenges of a case of primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid.

Authors:  Mathew M Palakkamanil; Muhammad N Mahmood; Audrey Chan
Journal:  BMC Ophthalmol       Date:  2020-10-14       Impact factor: 2.209

4.  Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents.

Authors:  Lei-Chi Wang; Tai-Chi Lin; Yi-Chen Yeh; Hsiang-Ling Ho; Chieh-Chih Tsai; Teh-Ying Chou
Journal:  Curr Oncol       Date:  2021-02-16       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.